These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 35635250

  • 1. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
    Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C.
    J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C, Kozma C, Patel C, Benson C, Yunusa I, Zhao P, Reeder G, Narasimhan M, Bank RL.
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [Abstract] [Full Text] [Related]

  • 4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [Abstract] [Full Text] [Related]

  • 5. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M, Lin D, Lafeuille MH, Ghelerter I, Morrison L, Lefebvre P, Joshi K.
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [Abstract] [Full Text] [Related]

  • 6. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [Abstract] [Full Text] [Related]

  • 7. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
    Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C.
    Curr Med Res Opin; 2023 Aug; 39(8):1157-1166. PubMed ID: 37461233
    [Abstract] [Full Text] [Related]

  • 8. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
    Tidmore LM, Keast SL, Waters HC, Pareja KL, Cothran T, Skrepnek GH.
    Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A, Xie L, Kariburyo F, Zhang Q, Gore M.
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [Abstract] [Full Text] [Related]

  • 11. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C.
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [Abstract] [Full Text] [Related]

  • 12. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ, Pesa JA, Lakey S, Benson C.
    BMC Psychiatry; 2022 Apr 09; 22(1):250. PubMed ID: 35395757
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
    Mahabaleshwarkar R, Lin D, Joshi K, Fishman J, Blair T, Hetherington T, Palmer P, Patel C, Krull C, Tcheremissine OV.
    J Ment Health Policy Econ; 2021 Jun 01; 24(2):47-59. PubMed ID: 34151777
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P.
    CNS Drugs; 2021 May 01; 35(5):469-481. PubMed ID: 33909272
    [Abstract] [Full Text] [Related]

  • 17. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
    Lauriello J, Weiden PJ, Gleeson CD, Shah A, Boulanger L, Jariwala-Parikh K, Hedgeman E, O'Sullivan AK.
    CNS Drugs; 2021 Oct 01; 35(10):1123-1135. PubMed ID: 34546558
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC, Marcoux RM, Quilliam BJ.
    J Manag Care Pharm; 2010 Jun 01; 16(5):317-28. PubMed ID: 20518584
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.